Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Omkar PharmachemBOM:532167 52 PB Ratio is 0.45 as of Jul. 29, 2026, which is 81% below its 10-year median of 2.40. GuruFocus rates BOM:532167 with a GF Score™ of 52/100 and a GF Value™ of ₹23.90 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 1,045 Business Services companies, Omkar Pharmachem ranks better than 91.48% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-29), Omkar Pharmachem's share price is ₹16.30. Omkar Pharmachem's Book Value per Share for the quarter that ended in Mar. 2026 was ₹36.33. Hence, Omkar Pharmachem's PB Ratio of today is 0.45.
Good Sign:
Omkar Pharmachem Ltd stock PB Ratio (=0.43) is close to 10-year low of 0.43.
The historical rank and industry rank for Omkar Pharmachem's PB Ratio or its related term are showing as below:
BOM:532167'
s PB Ratio Range Over the Past 10 Years
Min: 0.43 Med: 2.4 Max: 3.12
Current: 0.45
During the past 13 years, Omkar Pharmachem's highest PB Ratio was 3.12. The lowest was 0.43. And the median was 2.40.
BOM:532167's PB Ratio is ranked better than 91.48% of 1045
companies
in the Business Services industry
Industry Median: 1.65
vs BOM:532167: 0.45
During the past 12 months, Omkar Pharmachem's average Book Value Per Share Growth Rate was 288.40% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 59.40% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 23.60% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 6.70% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Omkar Pharmachem was 59.40% per year. The lowest was -3.40% per year. And the median was -0.20% per year.
Back to Basics: PB Ratio
Omkar Pharmachem (BOM:532167) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Omkar Pharmachem PB Ratio Related Terms
Omkar Pharmachem PB Ratio Historical Data
* Premium members only.
The historical data trend for Omkar Pharmachem's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:532167 vs CTAS, CPRT, GPN: PB Ratio Comparison
For the Specialty Business Services subindustry, Omkar Pharmachem's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Omkar Pharmachem PB Ratio vs Business Services Industry
For the Business Services industry and Industrials sector, Omkar Pharmachem's PB Ratio distribution charts can be found below:
* The bar in red indicates where Omkar Pharmachem's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Omkar Pharmachem (BOM:532167) has a PB Ratio of 0.45 as of Jul. 29, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Omkar Pharmachem and its competitors. This is 81% below median its historical median of 2.40. Over the past decade, Omkar Pharmachem's PB Ratio has ranged from 0.43 to 3.12. According to the industry distribution chart, Omkar Pharmachem ranks #89 out of 1045 companies in the Business Services industry, placing it in the top 8.5%.
Is Omkar Pharmachem's PB Ratio too high?
Omkar Pharmachem's current PB Ratio of 0.45 is 81% below median its 10-year median of 2.40. Over the past 10 years, this metric has ranged from a low of 0.43 to a high of 3.12. The Business Services industry median PB Ratio is 1.65. Omkar Pharmachem's value of 0.45 is 72.7% below this industry median. Based on the distribution chart, Omkar Pharmachem ranks #89 out of 1045 companies in the Business Services industry, which is in the top quartile — a strong position relative to peers. Overall, Omkar Pharmachem has a GF Score™ of 52/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Omkar Pharmachem's PB Ratio compare to CTAS and CPRT?
According to the Business Services industry distribution chart, Omkar Pharmachem ranks #89 out of 1045 companies for PB Ratio. This places Omkar Pharmachem in the top 9% of its industry — outperforming the majority of peers. The industry median PB Ratio is 1.65. Omkar Pharmachem's value of 0.45 is 72.7% below this benchmark. Historically, Omkar Pharmachem's own PB Ratio has ranged from 0.43 to 3.12 over the past decade. While the company's 10-year median is 2.40 vs. the industry median of 1.65, Omkar Pharmachem has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Business Services company?
The median PB Ratio among Business Services companies is 1.65, based on 1,045 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Omkar Pharmachem's current PB Ratio of 0.45 is 72.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Omkar Pharmachem and its competitors. For the Business Services industry, the median PB Ratio is 1.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Omkar Pharmachem's current PB Ratio is 0.45, which is 81% below median its own 10-year median of 2.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Omkar Pharmachem stock overvalued right now?
Based on GuruFocus' analysis, Omkar Pharmachem (BOM:532167) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹23.90, compared to a current price of ₹16.30 — trading 31.8% below its estimated fair value. The current PB Ratio is 0.45, which is 81% below median its 10-year median of 2.40 and 72.7% below the Business Services industry median of 1.65. Omkar Pharmachem's overall GF Score™ is 52/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Omkar Pharmachem (BOM:532167), the current PB Ratio is 0.45 as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Omkar Pharmachem (BOM:532167) Overvalued in 2026?
Based on GuruFocus' analysis, Omkar Pharmachem stock appears to be undervalued.
The current stock price of ₹16.30 is trading 31.8% below its estimated GF Value™ of ₹23.90.
GuruFocus considers Omkar Pharmachem to be Significantly Undervalued.
Key valuation signals for BOM:532167:
PB Ratio: 0.45 (81% below median its 10-year median of 2.40)
GF Value™: ₹23.90 vs. price of ₹16.30 (31.8% below fair value)
Industry Position: 72.7% below the Business Services median (#89 of 1045)
No single metric tells the full story. See the BOM:532167 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:532167 has been successfully added to your 
